| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Pixantrone |
| Brand | Pixuvri® |
| Indication | Is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non-Hodgkin B-cell Lynmphomas (NHL). |
| Assessment Process | |
| Rapid review commissioned | 10/02/2015 |
| Rapid review completed | 20/03/2015 |
| Rapid review outcome | Full Pharmacoeconomic Evaluation not Recommended |